Dr Seth Berkley, GAVI CEO, started the Mid-Term Review with an all-encompassing presentation highlighting the Alliance’s progress in delivering against its 2011-15 strategic goals. Read the A-Z of the key themes.
When we entered this period from 2011-2015, it was the first
time we had a five-year strategy. We had clear objectives, we had 18 key
performance indicators (KPIs). This is our opportunity to take a look at progress two
It’s very important to us that we are as transparent as
possible. We are the stewards of our donor’s resources: the dollars, the
pounds, the yen, and so we were delighted that just this last week, a major
report was released on aid transparency. In this report, we’re
ranked second in the world.
Four million future deaths averted: how do you picture those
numbers. One way to do is to look at what it means in other circumstances.
million is equivalent to all of the babies born each year in the United States.
We also talked about 243 million additional children immunised. That is half the
children immunised in the world during this time period.
What we’ve tried to do here is take a look at the KPIs and assess how likely we think it is that we will meet
them by 2015. Obviously things can happen between now and 2015, but what you
can see in the green is that for most of our indicators we think it’s quite
likely that we’re going to meet those goals. There’s a few for which it’s not
the case and we are working hard to change the way we work on those.
We have these large mission goals and the first one is under
five mortality rates in GAVI-eligible countries. We’re on target. Many things
affect child mortality not just immunisation, but immunisation is one of the
most cost effective and successful interventions.
The other two mission indicators: 3.9 million deaths averted
through routine immunisation and you can see again we’re on track for this. One
question people might ask is why is it that the curve heads up and the answer
is that as we immunise more children, more and more countries roll vaccines
The third indicator of 243 million additional children immunised: you can
see that we’re actually above this right now.
Acceleration of vaccine introductions
Since GAVI began, and you look at every vaccine that we’ve
ever done, we’ve actually rolled out about a fifth of all the vaccines during
this year, and about a quarter of all the launches that have occurred in the 13
years of GAVI occur this year.
In fact we’re doing more. 106 million people up until now have been reached through campaigns, 84 million through meningitis campaigns
and another 22 million through yellow fever campaigns. That’s on top of the
immunisations that we promised [Note: refers to 2011-2012].
91 percent of pledges have become signed agreements – that’s
one of our KPIs. And the countries that haven’t are trying hard. Just yesterday,
my country, the United States, managed to get their contribution of 138 million
dollars in the bank bringing their contributions to over one billion dollars to
GAVI. One of our challenges is that these last set of pledges get turned into
signed agreements and obviously capital.
Private sector partnerships
The Matching Fund brings in not only money but expertise
from the private sector. We have many examples of working with innovative
partnerships that will make a huge difference. The Lions Club: 1.35 million
volunteers on the ground helping with immunisation. These are innovative
partnerships that will make a huge difference.
Countries sharing the cost of vaccines
You can see that we’ve had increasing amounts of co-financing
from countries. To talk about an ambitious goal, this level is set at 100
percent. We’ve hovered between 86 and 93 percent. In development I don’t know
of any other example that is as ambitious as this.
More affordable vaccines
We’ve seen prices fall. In the last two years, prices have
fallen 35 percent for the three key vaccines. This is a reduction of cost
for the donors. It’s also going to be a reduction of costs in the future. We’ll
continue to see these prices fall.
Pentavalent success story
At the time this period started (2011), pentavalent had been
in 65 countries. It’s moved now to 72 countries. There’s only South Sudan left,
which of course wasn’t a country when this period started. We’re excited that South Sudan is on track for
the first quarter in 2014 to rollout this vaccine. This is an extraordinary
Women and girls
We’ve also started to bring forward vaccines that were
targeted specifically at women and girls. In the short period that we have
begun to discuss human papillomavirus vaccines and begun to have programmes, 25 countries have
stepped up to the plate and said we want this vaccine. This is a really important addition.
Equity is a very important part of what we do. Our partners,
UNICEF and WHO, have really stepped up to the plate. We’ve invested significant
more finance in trying to deal with the lower coverage countries, putting in
country tailored approaches, also in the countries that have the largest
inequities. We have a plan as we always do at GAVI to try and tackle the
Working with the Global Polio Initiative
One other big intervention that’s occurred during this
period is the work with the Global Polio Initiative, to take advantage of the
science they have in management and to work with them in trying to look at
routine immunisation. This is Uttar Pradesh, and here you can see a mapping of
looking at immunisation rates by polio staff. Working with other
partners is critical to the type of success that we want.
We have to sustain the work that we’re doing. Sustainability
relates to many different issues: legislation, budget lines, national
financing, political commitment. Today, 62 of the GAVI countries have budget
lines for routine vaccines.
Beyond the promise
We are on track for the big mission goals but it isn’t only
what we promised to do. We’re actually
going to immunise an additional 400 million children through campaigns, meaning
550 unique individuals. This is extraordinary.